Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.

Lancet series highlights a vicious circle of inequities hobbling efforts to end disease spread
Steeped in inequities that include formidable barriers to basic health services for multitudes of its most vulnerable, marginalized and neglected people, the country leading global HIV […]

Cost of pandemic includes setbacks to South Africa tuberculosis testing, diagnoses
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]

CDC urges physicians, parents to be on lookout for AFM, a polio-like illness seen predominately in children
With 2018 data showing highest incidence acute flaccid myelitis since monitoring began, officials say awareness, recognition of rare life threatening condition will be crucial to early […]

As environmental destruction accelerates the spread of emerging infections, we need to talk
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]
Pingback: Race, Sex, and Clinical Outcomes in Early HIV Infection | Liver cancer Blog
Pingback: World TB experts convene, work to blaze the trail to slow disease spread | Science Speaks: HIV & TB News